argenx agreed to buy Dallas‑based Forte for about $2.2 billion, folding Forte’s experimental anti‑CD122 drug FB102 into argenx’s immunology lineup.

A split 5th Circuit panel halted Texas’ monitoring-and-filtering mandate in the SCOPE Act while leaving age‑verification rules intact.

A new Dallas Morning News analysis maps OpenAI/UPenn exposure scores onto DFW jobs; customer service ranks high while fast-food — the region’s largest employer — shows low exposure.